Cabaletta Bio Reports Q2 2026 Results, Cash Runway to Mid-2027, and Key Clinical Milestones
CABA has more than doubled off its 52-week low of $1.26.
Summary
Cabaletta Bio reported Q2 2026 financial results with a $51.0M net loss and $225.1M in cash, funding operations into mid-2027. The company also provided key clinical updates, including registrational data expected in mid-2027 and a new SSc-ILD cohort starting in 4Q26.
Key Events · Earnings and Guidance · CABA
-
Q2 2026 Financial Results
Net loss of $51.0 million, with R&D expenses of $44.4 million and G&A of $7.6 million. Cash position of $225.1 million as of June 30, 2026.
-
Cash Runway Extended to Mid-2027
Management expects the $225.1 million cash balance to fund operations into mid-2027, consistent with prior guidance.
-
Registrational Myositis Data on Track
RESET-Myositis registrational cohort data expected in mid-2027, with a BLA submission planned for 2H27 if successful.
-
New SSc-ILD Cohort to Initiate in 4Q26
A single-arm registrational study in approximately 25 patients with SSc-associated ILD is anticipated to begin in 4Q26.
Analysis · CABA · Life Sciences
Cabaletta Bio reported a net loss of $51.0 million for Q2 2026, with R&D expenses rising to $44.4 million as the company advances its rese-cel CAR T therapy. The company holds $225.1 million in cash, which it expects to fund operations into mid-2027. The filing also provides a detailed clinical update: registrational RESET-Myositis data is on track for mid-2027 with a BLA submission planned for 2H27, a new SSc-associated ILD cohort of approximately 25 patients is set to initiate in 4Q26, and the PC-free approach is being incorporated into RESET-MG. These milestones are material for a late-stage biotech with a going-concern warning, as they define the path to potential approval and the timeline for capital needs.
At the time of this filing, CABA was trading at $2.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $464.7M. The 52-week trading range was $1.26 to $4.23. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.